Medical & Healthcare

Veriskin: Linux Expertise And Qt Development

Homepage Veriskin: Linux Expertise And Qt Development

Project Background

Veriskin is an American medical device startup developing a noninvasive skin cancer screening device. Based on a Qualcomm Snapdragon 410 processor, Veriskin’s handheld device is an innovative solution which deter-mines whether a suspect skin growth is cancerous less than two minutes.
Veriskin’s skin cancer detection device is an advanced medical Wi-Fi enabled solution, utilizing all the capabilities of a FPGA (Field Programmable Gate Array) coupled with LEDs to detect skin condition with a simple scan.

While developing this innovative skin cancer screening device, Veriskin was seeking a partner with an extensive embedded Linux software expertise, combined with a strong experience on Qt graphical user interface development .

Veriskin is the kind of company we strive to work with. What could be better than allowing the medical market to make great progress whilst helping a countless number of people? We are thrilled to collaborate with Veriskin, on a software point of view, to develop the next generation of skin cancer detection equipment. This project is a great example of Witekio’s deep system software understanding and expertise in embedded and application development. Sébastien Ronsse, Witekio US site manager


Witekio provided a complete set of software services to develop the technical solution. This set of services in-cludes low level software development, from Board Support Package development, to boot-time improvement up to graphical user interface application development.
With regards to low level embedded development, Witekio managed to port and adapt a custom Linux Board Support Package on Veriskin’s device based Variscite System on Module Qualcomm Snapdragon 410. This Linux BSP supports the on-board hardware components of the System on Module (esp. connectivity features, such as Wi-FI).

These low level developments enable the end user to benefit from all the functionalities of a Linux operating system combined with the raw performance and perks of the Qualcomm processor.
The BSP adaptation includes the optimization of the Linux kernel to fully support the device’s screen, as well as a full set of drivers tests to ensure greater reliability of the equipment.

As a final step of software collaboration, Witekio ensured the device’s boot time improvement as well as the development of an attractive and innovative Qt5 user interface application, including the features and ad-vantages of the Qt 5 graphical framework.


A multi-layer software development and support service.

  • Complete embedded software service from board bring-up, to Linux Board Support Package adaptation and Qt5 graphical application
  • Seamless Linux custom BSP and drivers adaptation
  • Time saving thanks to our Linux kernel BSP legacy expertise and our Qt technology proficiency
  • Product reliability enhancement and performance optimization
Witekio provided Veriskin with a talented, experienced and attentive team focused on execution and meeting the company deadlines. The Witekio team was professional, engaged and made us feel as if we were all one company” Nelson Quintana - Vice President of Engineering at Veriskin Inc

Key facts

  • The system developed covers all the value chain of an embedded project
  • Custom Linux BSP and drivers adaptation
  • Using all the advantages of Qt5 graphical framework to create an immersive graphical user interface
  • Linux boot-time optimization

Veriskin, Inc. is a medical device startup focusing on developing a noninvasive device for skin cancer screening. Skin cancer is the most common form of cancer in the US, accounting for just under half of all cancers or 5.4 million diagnoses annually. An estimated $5.8 billion is spent on dermatology visits and skin biopsies each year to determine whether a suspect skin lesion is cancerous or not. Veriskin has developed a novel, low-cost, inexpensive method and handheld device for non-invasive skin cancer screening which determines if a suspect skin growth is cancerous in ~ 2 min. We have demonstrated an unparalleled 100% sensitivity and 96.7% specificity in discriminating skin cancers from benign skin growths in recent clinical studies performed in multiple dermatology clinics in CA and AZ. Anticipated savings to the US healthcare industry and insurers are estimated at $3.2B through reduction of unnecessary biopsies and referrals to dermatologists. In 2016 Veriskin, Inc. has been awarded a SBIR Phase II grant award by the National Cancer Institute of the NIH.